Kruse Bo

About Kruse Bo

Bo Kruse is an अनुभanced finance executive in the biopharmaceutical sector, best known for serving as Chief Financial Officer, Treasurer, and Secretary of Y-mAbs Therapeutics, Inc., a Nasdaq-listed company focused on antibody-based cancer therapies. His career reflects deep international experience in corporate finance, capital markets, accounting, and financing activities, built through senior leadership roles in biotechnology companies. Before joining Y-mAbs, he served as Chief Financial Officer of the Danish biotech company Azanta A/S from 2009 to 2015. Prior to that, he held multiple finance leadership positions at Genmab A/S from 2000 to 2008, including Vice President and Chief Financial Officer from 2005 to 2008 and Vice President and Chief Accounting Officer from 2000 to 2005. During his eight-year tenure at Genmab, he was directly involved in several financing rounds, including the company’s initial public offering, which highlights his experience in high-stakes capital formation and public-market readiness. At Y-mAbs, Kruse played an important role in supporting the company’s growth and financial discipline over a multi-year period, helping guide the organization through the demands of a commercial-stage biopharmaceutical business. His departure was announced in 2024, with a transition period to ensure continuity in the finance function. Overall, his background positions him as a seasoned life-sciences finance leader with experience spanning public-company governance, fundraising, accounting oversight, and strategic financial management in international markets.